MedMatrix Rx
Daily 340B Morning Briefing for Hospital and Clinic Executives
Johnson & Johnson’s new 340B claims data requirement takes effect soon, impacting covered entities’ access to drug pricing. ASHP advocates on Capitol Hill for 340B program protections. Multiple active court cases continue to shape the 340B landscape, with significant legal actions involving major pharmaceutical companies. Stakeholders are closely monitoring CMS’s proposed 2027 payment changes, which could significantly affect 340B reimbursement.
EXECUTIVE SUMMARY
01
Johnson & Johnson imposes new 340B claims data requirement.
Starting September 15, Johnson & Johnson will require 340B covered entities to submit claims-level data to maintain 340B pricing.
Starting September 15, Johnson & Johnson will require 340B covered entities to submit claims-level data to maintain 340B pricing.
Source: Becker’s Hospital Review
02
ASHP lobbies for 340B protections on Capitol Hill.
ASHP members met with congressional offices on September 16 to advocate for 340B program protections and expanded Medicare coverage for pharmacist-provided care.
ASHP members met with congressional offices on September 16 to advocate for 340B program protections and expanded Medicare coverage for pharmacist-provided care.
Source: Becker’s Hospital Review
03
NASP comments on CMS’s proposed 340B payment changes.
NASP submitted comments addressing the potential implications of CMS’s proposed 2027 payment changes for 340B-acquired drugs.
NASP submitted comments addressing the potential implications of CMS’s proposed 2027 payment changes for 340B-acquired drugs.
Source: NASP
04
Froedtert Memorial Lutheran Hospital sues CVS over 340B diversion.
Froedtert alleges CVS diverted $18 million in 340B savings, filing suit on August 20 in the Eastern District of Wisconsin.
Froedtert alleges CVS diverted $18 million in 340B savings, filing suit on August 20 in the Eastern District of Wisconsin.
Source: Becker’s Hospital Review
05
Mount Sinai Hospital files lawsuit against CVS Health.
Mount Sinai Hospital filed a lawsuit in the Southern District of New York against CVS Health on September 11, 2026.
Mount Sinai Hospital filed a lawsuit in the Southern District of New York against CVS Health on September 11, 2026.
Source: CourtListener
06
AHA urges CMS to reconsider 2027 outpatient payment proposals.
AHA opposes CMS’s proposed 2027 payment changes, citing potential financial burdens on hospitals due to accelerated 340B repayment requirements.
AHA opposes CMS’s proposed 2027 payment changes, citing potential financial burdens on hospitals due to accelerated 340B repayment requirements.
Source: Becker’s Hospital Review
07
Pharmaceutical Research and Manufacturers of America v. Weiser ongoing.
The case in the District of Colorado involves challenges to 340B program regulations by pharmaceutical manufacturers.
The case in the District of Colorado involves challenges to 340B program regulations by pharmaceutical manufacturers.
Source: CourtListener
08
AbbVie Inc. v. Kennedy continues in D.C. court.
The lawsuit involves 340B program disputes, with recent court actions allowing additional parties to intervene.
The lawsuit involves 340B program disputes, with recent court actions allowing additional parties to intervene.
Source: CourtListener
09
Novartis Pharmaceuticals Corp. v. Hanaway in 8th Circuit.
The appellate case addresses 340B program compliance issues involving the Missouri Attorney General.
The appellate case addresses 340B program compliance issues involving the Missouri Attorney General.
Source: CourtListener
10
AbbVie Inc. v. Torrez filed in New Mexico court.
The case involves ongoing legal challenges related to the 340B program, filed on September 14, 2026.
The case involves ongoing legal challenges related to the 340B program, filed on September 14, 2026.
Source: CourtListener
EXECUTIVE SUMMARY — KEY TAKEAWAYS
Most important 340B implication. Johnson & Johnson’s new claims data requirement for 340B pricing could set a precedent for other manufacturers, potentially increasing administrative burdens on covered entities. This move highlights the growing trend of drugmakers seeking more transparency and control over 340B discounts, which could impact the financial viability of participating entities.
Emerging risks.
- Covered entities face potential loss of 340B pricing if they fail to comply with J&J’s data submission requirement.
- Legal disputes over 340B program rules may lead to increased litigation costs for hospitals and health systems.
- CMS’s proposed payment changes could result in significant financial strain on hospitals, particularly those heavily reliant on 340B savings.
- Ongoing lawsuits involving major pharmaceutical companies may lead to further restrictions on 340B program access.
Emerging opportunities.
- ASHP’s advocacy efforts could lead to legislative changes that strengthen 340B program protections.
- Hospitals can engage with CMS during the comment period to influence 2027 payment rule outcomes.
- Participation in legal interventions may provide hospitals a platform to voice concerns and shape 340B policy.
- Collaboration with pharmacy organizations can improve lobbying efforts for favorable 340B program adjustments.
Key actions for providers.
- Ensure compliance with J&J’s new data submission requirement to maintain 340B pricing.
- Monitor ongoing litigation for developments that may impact 340B program participation.
- Submit comments to CMS regarding proposed 2027 payment changes to advocate for hospital interests.
- Engage with congressional representatives to support ASHP’s legislative priorities for the 340B program.
TOP STORIES
Johnson & Johnson imposes 340B claims data requirement.
Becker’s Hospital Review · September 11, 2026
- J&J requires 340B entities to submit claims data starting September 15 to maintain pricing.
- Noncompliance leads to pricing suspension, with restoration upon data submission.
ASHP advocates for 340B protections on Capitol Hill.
Becker’s Hospital Review · September 16, 2026
- ASHP seeks expanded Medicare coverage for pharmacist-provided care.
- Advocacy includes support for the Main Street Pharmacy Access Act and Equitable Community Access to Pharmacist Services Act.
Froedtert sues CVS for $18M in alleged 340B diversion.
Becker’s Hospital Review · August 31, 2026
- Froedtert alleges CVS diverted $18 million in 340B savings.
- The lawsuit was filed in the Eastern District of Wisconsin on August 20.
FEDERAL POLICY & REGULATORY DEVELOPMENTS
NASP comments on CMS’s proposed 340B payment changes.
NASP · September 1, 2026
- NASP addresses implications of CMS’s proposed 2027 payment changes.
- Comments focus on reimbursement for 340B-acquired drugs and specialty pharmacy services.
AHA urges CMS to reconsider 2027 payment proposals.
Becker’s Hospital Review · August 26, 2026
- AHA opposes CMS’s accelerated 340B repayment requirements.
- Hospitals face potential financial burdens from proposed payment changes.
Hospital groups urge CMS to pull back 2027 outpatient rule.
Becker’s Hospital Review · August 31, 2026
- AHA, AAMC, and AMGA submitted comments opposing key provisions.
- Concerns include 340B drug payment cuts and site-neutral payment expansion.
340B PROGRAM DEVELOPMENTS
Johnson & Johnson requires 340B claims data for discounts.
Healthcare Dive · September 14, 2026
- J&J’s policy aims to prevent duplicative discounts.
- The requirement applies to all covered entity types.
LITIGATION & ENFORCEMENT WATCH
| Court | Matter | Date |
|---|---|---|
| M.D. Fla. | The Elevance Health Companies, Inc. v. Senderra Rx Partners, LLC [source] | September 4, 2026 |
| D.D.C. | COREWELL HEALTH WILLIAM BEAUMONT UNIVERSITY HOSPITAL v. KENNEDY [source] | September 3, 2026 |
| D. Maryland | State of New York v. U.S. Department of Health and Human Services [source] | August 27, 2026 |
| E.D. Wis. | Froedtert Memorial Lutheran Hospital Inc v. CVS Health Corporation [source] | August 20, 2026 |
| E.D. Pa. | AZURITY PHARMACEUTICALS, INC. v. GITOMER [source] | August 17, 2026 |
| M.D. Fla. | Azurity Pharmaceuticals, Inc. v. Bhattacharya [source] | August 17, 2026 |
| N.D. Ill. | ASTRAZENECA PHARMACEUTICALS LP v. KWAME RAOUL, in his official capacity as ATTORNEY GENERAL of the STATE OF ILLINOIS [source] | August 14, 2026 |
| 8th Cir. | AbbVie, Inc. v. Marty Jackley [source] | August 11, 2026 |
| N.D. Ill. | AbbVie Inc. v. Raoul [source] | August 7, 2026 |
| 8th Cir. | Novartis Pharmaceuticals Corp. v. Catherine L. Hanaway (25-1619) [source] | September 16, 2026 |
| D.N.M. | AbbVie Inc. v. Torrez (1:25-cv-01230-KG-JHR) [source] | September 14, 2026 |
| S.D.N.Y. | Mount Sinai Hospital v. CVS Health Corporation (1:26-cv-04143) [source] | September 11, 2026 |
| D. Colo. | Pharmaceutical Research and Manufacturers of America v. Weiser (1:25-cv-02437-RMR-STV) [source] | September 1, 2026 |
| D.D.C. | ABBVIE INC. v. KENNEDY (1:26-cv-1190-RDM) [source] | August 24, 2026 |
MANUFACTURER WATCH
| Manufacturer | Action | Date |
|---|---|---|
| Johnson & Johnson | Requires 340B covered entities to submit claims data for pricing. [source] | September 11, 2026 |
SOCIAL MEDIA & STAKEHOLDER SENTIMENT
Recent commentary on the U.S. 340B Drug Pricing Program was identified by searching for statements, op-eds, and advocacy positions from hospital and health-center groups, provider and patient advocates, drug manufacturers, PBMs, and policy commentators within the last 90 days, focusing on reputable sources such as official organizational websites, government publications, and established news outlets.
Fact Sheet: A 340B Rebate Model Would Undermine Access to Care
American Hospital Association (AHA) · August 7, 2026
- Main theme: AHA’s opposition to a proposed 340B rebate model replacing upfront discounts.
- Stakeholder sentiment: AHA expresses strong opposition to the rebate model, stating it would “undermine access to care” and “shift the financial risk to 340B covered entities.”
- Potential implications: Potential delays in patient care and financial strain on safety-net hospitals.
- Credibility: AHA is a reputable organization representing hospitals and health systems.
WHAT TO WATCH NEXT
- Johnson & Johnson’s 340B claims data requirement takes effect on September 15, 2026. [source]
- Monitor CMS’s response to NASP and AHA comments on the 2027 payment rule. [source]
- Watch for developments in the Froedtert v. CVS lawsuit regarding 340B diversion. [source]
- Track legislative progress on ASHP’s advocated bills for 340B protections. [source]
End of briefing.
This briefing is provided for informational purposes only and does not constitute legal, regulatory, financial, or compliance advice. Automated summarization may contain errors or omissions, and source materials may change after publication. Recipients should independently verify all information against the cited primary sources before relying on it.
© 2026 MedMatrix Rx. All rights reserved.